Drugs / CS-206
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07000318 | Sep 2026 → Dec 2028 expected | sickle cell disease | Children's Hospital of Fudan University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06565026 | Sep 2024 → Dec 2026 expected | sickle cell disease | CorrectSequence Therapeutics Co., Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-09-07 | CorrectSequence Therapeutics Co., Ltd | Results Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds correctsequence.com ↗
All achieved rapid hematopoietic reconstitution, sustained high-level pan-cellular HbF expression, complete transfusion independence or freedom from vaso-occlusive crises (VOCs), with no detectable off-target edits, or product-related adverse events. |
| 2026-06-02 | CorrectSequence Therapeutics Co., Ltd | Results High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease correctsequence.com ↗
CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for severe diseases, announced that the first sickle cell disease (SCD) patient being treated in China with its high-precision base-editing therapy CS-206 has remained free of vaso-occlusive crises (VOCs) for more than 15 months following engraftment. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-07 | CorrectSequence Therapeutics Co., Ltd | Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds correctsequence.com ↗ |
| 2026-06-02 | CorrectSequence Therapeutics Co., Ltd | High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease correctsequence.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS-206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06565026 ↗ |
| Action | Restore | “can re-induce the production of γ-globin chain and increase the concentration of fetal hemoglobin(HbF) in the blood, compensating for the function of missing adult hemoglobin HbA” NCT06565026 ↗ |
| Modality | Cell therapy | “Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique” NCT06565026 ↗ |